REGENERON PHARMACEUTICALS, INC. — fact timeline

REGENERON PHARMACEUTICALS, INC. shareholders approved Advisory Vote on Executive Compensation at the 2026-06-12 meeting.

“Proposal 3 – Advisory Vote on Executive Compensation The resolution to approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement on Schedule 14A filed April 24, 2026 was approved based upon the following votes: For: 96,469,374 Against: 6,898,268 Abstain: 105,512 Broker Non-Votes: 5,543,411”

REGENERON PHARMACEUTICALS, INC. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-06-12 meeting.

“Proposal 2 – Ratification of Appointment of Independent Registered Public Accounting Firm The proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was approved based upon the following votes: For: 102,503,788 Against: 6,443,958 Abstain: 68,819”

REGENERON PHARMACEUTICALS, INC. shareholders approved Election of Directors at the 2026-06-12 meeting.

“Proposal 1 – Election of Directors The following nominees for Class II directors were elected to serve until the 2027 Annual Meeting of Shareholders and until their successors are duly elected and qualified based upon the following votes: Nominee For Against Abstain Broker Non-Votes Joseph L. Goldstein, M.D. 72,398,297 30,904,254 170,603 5,543,411 Christine A. Poon 79,409,070 24,004,880 59,204 5,543,411 David P. Schenkein, M.D. 99,241,219 4,180,107 51,828 5,543,411 Craig B. Thompson, M.D. 81,933,651 21,378,567 160,936 5,543,411 Huda Y. Zoghbi, M.D. 100,665,234 2,698,397 109,523 5,543,411”

REGENERON PHARMACEUTICALS, INC. reported preliminary financial results for first quarter 2026.

“Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”) currently expects that its financial results calculated in accordance with U.S. generally accepted accounting principles (“ GAAP ”) and its non-GAAP financial results for the first quarter 2026 will include an acquired in-process research and development (“ IPR&D ”) charge of approximately $102 million on a pre-tax basis.”

REGENERON PHARMACEUTICALS, INC. reported financial results for first quarter of 2024.

“On May 2, 2024, Regeneron Pharmaceuticals, Inc. issued a press release announcing its financial and operating results for the quarter ended March 31, 2024.”

REGENERON PHARMACEUTICALS, INC. reported the quarter and year ended December 31, 2023 results: revenue $3.43 billion (Q4 2023), $13.12 billion (Full year 2023), net income $1,160 million (Q4 2023 GAAP), $3,954 million (Full year 2023 GAAP), EPS $10.19 per diluted share (Q4 2023 GAAP), $34.77 per diluted share (Full year 2023 GAAP).

“On February 2, 2024, Regeneron Pharmaceuticals, Inc. issued a press release announcing its financial and operating results for the quarter and year ended December 31, 2023.”

Jason Pitofsky was appointed as Vice President, Controller at REGENERON PHARMACEUTICALS, INC..

“appointed Jason Pitofsky, currently the Company’s Vice President, Accounting and Financial Reporting, as Vice President, Controller.”

Christopher Fenimore was appointed as Senior Vice President, Finance and Chief Financial Officer at REGENERON PHARMACEUTICALS, INC..

“appointed Christopher Fenimore, currently the Company’s Senior Vice President, Controller, as Senior Vice President, Finance and Chief Financial Officer”

Robert E. Landry departed as Chief Financial Officer at REGENERON PHARMACEUTICALS, INC..

“the current Chief Financial Officer, Robert E. Landry, who is retiring.”

REGENERON PHARMACEUTICALS, INC. reported fourth quarter 2023 results: EPS $0.21.

“the Company’s preliminary (unaudited) fourth quarter 2023 U.S. net product sales of EYLEA ® HD (aflibercept) Injection 8 mg of approximately $123 million and the Company’s preliminary (unaudited) fourth quarter 2023 U.S. net product sales of EYLEA ® (aflibercept) Injection of approximately $1.34 billion”

REGENERON PHARMACEUTICALS, INC. reported the quarter ended September 30, 2023 results: revenue $3,363, net income $1,008, EPS $8.89.

“to our portfolio through the recent acquisition of Decibel Therapeutics." Financial Highlights ($ in millions, except per share data) Q3 2023 Q3 2022 % Change Total revenues $ 3,363 $ 2,936 15 % GAAP net income $ 1,008 $ 1,316 (23 %) GAAP net income per share - diluted $ 8.89 $ 11.66 (24 %) Non-GAAP net income (a) $ 1,329 $ 1,270 5 % Non-GAAP net income per”

David P. Schenkein was elected as Class II Director at REGENERON PHARMACEUTICALS, INC..

“Regeneron’s board of directors (the “ Board ”) elected Kathryn Guarini, Ph.D. as a Class III director and David P. Schenkein, M.D. as a Class II director to fill the two vacancies on the Board.”

Kathryn Guarini was elected as Class III Director at REGENERON PHARMACEUTICALS, INC..

“Regeneron’s board of directors (the “ Board ”) elected Kathryn Guarini, Ph.D. as a Class III director and David P. Schenkein, M.D. as a Class II director to fill the two vacancies on the Board.”

Christopher Fenimore was appointed as Chief Financial Officer at REGENERON PHARMACEUTICALS, INC..

“The Company intends to appoint Christopher Fenimore, currently the Company’s Senior Vice President, Controller, to succeed Mr. Landry as Chief Financial Officer of the Company effective upon Mr. Landry’s retirement.”

Robert E. Landry departed as Executive Vice President, Finance and Chief Financial Officer at REGENERON PHARMACEUTICALS, INC..

“On September 8, 2023, Robert E. Landry notified the Company of his intention to retire from his position as Executive Vice President, Finance and Chief Financial Officer of the Company in February 2024.”

Marc Tessier-Lavigne retired as Director at REGENERON PHARMACEUTICALS, INC..

“On September 1, 2023, Marc Tessier-Lavigne, Ph.D. notified Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”) of his decision to retire, effective as of that date, as a director of the Company.”

REGENERON PHARMACEUTICALS, INC. shareholders approved Advisory vote on the frequency of future shareholder votes on executive compensation at the 2023-06-09 meeting.

“As reported by the Company in the Original Report, a frequency of every one year received a majority of the votes cast on the proposal.”

REGENERON PHARMACEUTICALS, INC. reported the quarter ended June 30, 2023 results: revenue $3.16 billion, EPS $8.50.

“EXHIBIT 99.1 Document Exhibit 99.1 Press Release Regeneron Reports Second Quarter 2023 Financial and Operating Results • Second quarter 2023 revenues increased 11% to $3.16 billion versus second quarter 2022 • Second quarter 2023 Dupixent ® global net sales (recorded by Sanofi) increased 33% to $2.79 billion versus second quarter 2022 • Second quarter 2023”

REGENERON PHARMACEUTICALS, INC.: Amendment to by-laws to permit election of two Co-Chairs of the Board, with either Co-Chair able to exercise full powers (effective 2023-06-09).

“The Amendment provides that the Board from time to time may elect two persons to serve as Co-Chairs of the Board and that, if there are Co-Chairs, either Co-Chair may exercise the full powers and authorities of the office.”

REGENERON PHARMACEUTICALS, INC. shareholders rejected Non-binding shareholder proposal requesting report on process by which access to medicine is considered in matters related to protecting intellectual property at the 2023-06-09 meeting.

“Proposal 5 – Non-binding Shareholder Proposal Requesting Report on a Process by which Access to Medicine is Considered in Matters Related to Protecting Intellectual Property The non-binding shareholder proposal requesting report on a process by which access to medicine is considered in matters related to protecting intellectual property was not approved based upon the following votes: For: 10,554,422 Against: 101,359,081 Abstain: 603,791 Broker Non-Votes: 4,209,777”

REGENERON PHARMACEUTICALS, INC. shareholders approved Advisory vote on the frequency of future advisory votes on executive compensation at the 2023-06-09 meeting.

“Proposal 4 – Advisory Vote on Frequency of Future Advisory Votes on Executive Compensation One year was selected by a majority of the votes cast on the advisory proposal on the frequency of future advisory votes on executive compensation based upon the following votes: One Year: 111,204,155 Two Years: 56,571 Three Years: 1,192,972 Abstain: 63,596 Broker Non-Votes: 4,209,777”

REGENERON PHARMACEUTICALS, INC. shareholders approved Advisory vote to approve the compensation of named executive officers at the 2023-06-09 meeting.

“Proposal 3 – Advisory Vote on Executive Compensation The resolution to approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement was approved based on the following votes: For: 97,786,842 Against: 14,490,406 Abstain: 240,046 Broker Non-Votes: 4,209,777”

REGENERON PHARMACEUTICALS, INC. shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year 2023 at the 2023-06-09 meeting.

“Proposal 2 – Ratification of Appointment of Independent Registered Public Accounting Firm The proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023, was approved based upon the following votes: For: 112,392,480 Against: 4,290,618 Abstain: 43,973”

REGENERON PHARMACEUTICALS, INC. shareholders approved Election of Class II directors at the 2023-06-09 meeting.

“Proposal 1 – Election of Directors The following nominees for Class II directors were elected to serve until the 2026 Annual Meeting of Shareholders and until their successors are duly elected and qualified based upon the following votes: Nominee For Against Abstain Broker Non-Votes Joseph L. Goldstein, M.D. 78,930,855 33,390,357 196,082 4,209,777 Christine A. Poon 84,515,116 27,751,062 251,116 4,209,777 Craig B. Thompson, M.D. 111,784,253 644,879 88,162 4,209,777 Huda Y. Zoghbi, M.D. 108,341,947 4,126,763 48,584 4,209,777”

REGENERON PHARMACEUTICALS, INC. reported financial results for the first quarter of 2023.

“On May 4, 2023, Regeneron Pharmaceuticals, Inc. issued a press release announcing its financial and operating results for the quarter ended March 31, 2023.”

Christine A. Poon was appointed as Lead Independent Director at REGENERON PHARMACEUTICALS, INC..

“and to designate Christine A. Poon as the Lead Independent Director of the Board”

George D. Yancopoulos was elected as Co-Chair of the Board at REGENERON PHARMACEUTICALS, INC..

“the Board plans to elect Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of the Company, and George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of the Company, as Co-Chairs of the Board”

Leonard S. Schleifer was elected as Co-Chair of the Board at REGENERON PHARMACEUTICALS, INC..

“the Board plans to elect Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of the Company, and George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of the Company, as Co-Chairs of the Board”

P. Roy Vagelos departed as Chair of the Board at REGENERON PHARMACEUTICALS, INC..

“Dr. Vagelos will continue to serve as Chair of the Board for the remainder of his term until the conclusion of the 2023 Annual Meeting.”

REGENERON PHARMACEUTICALS, INC. reported preliminary financial results for first quarter 2023.

“Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”) currently expects that its financial results calculated in accordance with U.S. generally accepted accounting principles (“ GAAP ”) and its non-GAAP financial results for the first quarter 2023 will include an acquired in-process research and development (“ IPR&D ”) charge of approximately $56 million on a pre-tax basis, primarily relating to an up-front payment in connection with the Company’s previously announced collaboration and license agreement with Sonoma Biotherapeutics, Inc.”

REGENERON PHARMACEUTICALS, INC. reported Fourth Quarter 2022 results: revenue $3,414 million, net income $1,197 million, EPS $10.50.

“99.1 Document Exhibit 99.1 Press Release Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results • Fourth quarter 2022 revenues decreased 31% to $3.41 billion versus fourth quarter 2021; excluding REGEN-COV ® and Ronapreve TM (a)(b) , revenues increased 14% • Full year 2022 revenues decreased 24% to $12.17 billion versus full year”

REGENERON PHARMACEUTICALS, INC. reported full year 2022 results: revenue approximately $6.26 billion.

“The presentation includes information regarding the Company’s preliminary (unaudited) U.S. net product sales of EYLEA ® (aflibercept) Injection of approximately $6.26 billion for the full year 2022 (based on preliminary (unaudited) fourth quarter 2022 U.S. net product sales of EYLEA of approximately $1.50 billion).”

REGENERON PHARMACEUTICALS, INC. incurred revolving credit of $750 million with JPMorgan Chase Bank, N.A. at variable interest rate based on SOFR or alternate base rate plus applicable marg maturing December 19, 2027.

“The Credit Agreement provides for a $750 million senior unsecured five-year revolving credit facility (with a $25 million sublimit for swingline borrowings and a $50 million sublimit for letters of credit)”

REGENERON PHARMACEUTICALS, INC. terminated Prior Credit Agreement with JPMorgan Chase Bank, N.A. valued at Prior $750 million revolving credit facility terminated (effective 2022-12-19).

“On the Closing Date, in connection with the entry into the Credit Agreement as described in Item 1.01 above, the Company terminated its then-existing credit agreement, dated as of December 14, 2018, as amended prior to the Closing Date (the “ Prior Credit Agreement ”), by and among Regeneron, as a borrower and guarantor; certain subsidiaries of Regeneron party thereto as subsidiary borrowers; the lenders and issuing banks from time to time party thereto; and JPMorgan Chase Bank, N.A., as administrative agent, swingline lender, and an issuing bank.”

REGENERON PHARMACEUTICALS, INC. entered into Credit Agreement with JPMorgan Chase Bank, N.A. valued at $750 million senior unsecured five-year revolving credit facility (effective 2022-12-19).

“On December 19, 2022 (the “ Closing Date ”), Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”) entered into a credit agreement (the “ Credit Agreement ”) by and among the Company, as a borrower and guarantor; certain direct subsidiaries of the Company, as the initial subsidiary borrowers; the lenders and issuing banks from time to time party thereto; and JPMorgan Chase Bank, N.A., as administrative agent, swingline lender, and an issuing bank. The Credit Agreement provides for a $750 million senior unsecured five-year revolving credit facility”

REGENERON PHARMACEUTICALS, INC. reported the quarter ended September 30, 2022 results: revenue $2.94 billion, net income $1,316 million, EPS $11.66.

“EXHIBIT 99.1 Document Exhibit 99.1 Press Release Regeneron Reports Third Quarter 2022 Financial and Operating Results • Third quarter 2022 revenues decreased 15% to $2.94 billion versus third quarter 2021; excluding REGEN-COV ® (a)(b) , revenues increased 11% • Third quarter 2022 EYLEA ® U.S. net sales increased 11% versus third quarter 2021 to a record”

Craig B. Thompson was elected as Director at REGENERON PHARMACEUTICALS, INC..

“On October 3, 2022, the board of directors (the “ Board ”) of Regeneron Pharmaceuticals, Inc. (the “ Company ”) elected Craig B. Thompson, M.D. as a director.”